Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial

por Chen, Gui-Ling, Li, Xiao-Feng, Dai, Xia-Hong, Li, Nan, Cheng, Meng-Li, Huang, Zhen, Shen, Jian, Ge, Yu-Hua, Shen, Zhen-Wei, Deng, Yong-Qiang, Yang, Shu-Yuan, Zhao, Hui, Zhang, Na-Na, Zhang, Yi-Fei, Wei, Ling, Wu, Kai-Qi, Zhu, Meng-Fei, Peng, Cong-Gao, Jiang, Qi, Cao, Shou-Chun, Li, Yu-Hua, Zhao, Dan-Hua, Wu, Xiao-Hong, Ni, Ling, Shen, Hua-Hao, Dong, Chen, Ying, Bo, Sheng, Guo-Ping, Qin, Cheng-Feng, Gao, Hai-Nv, Li, Lan-Juan
Publicado 2022